Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Adaptive Biotechnologies reports Q2 revenue growth of 22%, driven by MRD business expansion and plans to separate divisions.
ADPT
$23.41
+$0.30 +1.30%

Adaptive Biotechnologies reports Q2 revenue growth of 22%, driven by MRD business expansion and plans to separate divisions.

Company Fundamentals
29 Jul 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Adaptive Biotechnologies announced a 22% revenue increase to $71.6 million in Q2 2026, led by a 33% growth in its Minimal Residual Disease (MRD) segment, which accounted for 92% of revenue. The company completed a $345 million convertible notes offering to repay debt and improve financial flexibility. It plans to separate its MRD and Immune Medicine businesses to enhance shareholder value. Despite a net loss of $39.9 million, adjusted EBITDA loss narrowed significantly, and full-year MRD revenue guidance was raised to $268-$278 million, signaling confidence in growth prospects.

More News (ADPT)

Adaptive Biotechnologies shifts to MRD diagnostics with strong growth and profitability after Immune Medicine spin-off

Adaptive Biotechnologies shifts to MRD diagnostics with strong growth and profitability after Immune Medicine spin-off

Adaptive Biotechnologies is focusing on measurable residual disease (MRD) diagnostics by spinning off its Immune Medicine division, which revealed strong profitability. The company reported a 49% year-over-year growth in MRD revenue (excluding milest...

Company Fundamentals
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App